CriticalFourth-generation fluoroquinolone×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Moxifloxacin prolongs the heart-rate-corrected QT interval (QTc) on the electrocardiogram in some patients, and the prolongation may increase as the drug's blood level rises (moxifloxacin summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and moxifloxacin label, US Food and Drug Administration, FDA). Pimozide also prolongs the QT interval, so an additive effect on QT can be expected with other QT-prolonging drugs (pimozide FDA label). The Spanish moxifloxacin SmPC does not rule out an additive effect on the QT interval with other QTc-prolonging drugs, which may increase the risk of ventricular arrhythmias, including torsade de pointes (moxifloxacin SmPC, AEMPS). CYP3A4 and CYP2D6 are the main enzymes that metabolise pimozide, and higher pimozide levels may increase the risk of QT prolongation (pimozide SmPC, AEMPS). Moxifloxacin, however, is unlikely to interact with other drugs through cytochrome P450 enzymes (moxifloxacin SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. With long-term therapeutic doses of pimozide and in overdose, very rare cases of QT prolongation, ventricular arrhythmias and torsade de pointes have been reported, even in people without risk factors. Ventricular tachycardia and ventricular fibrillation, sometimes fatal, have also been reported (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With moxifloxacin, QT prolongation (common in people with low potassium), palpitations and fast heart rate are uncommon, ventricular tachyarrhythmias and fainting are rare, and torsade de pointes and cardiac arrest are very rare. Women and older people may be more sensitive to QT-prolonging drugs (moxifloxacin SmPC, AEMPS). Severe arrhythmias in pimozide overdose may be accompanied by low blood pressure and circulatory collapse (pimozide SmPC, AEMPS, overdose section).
Management
The combination is contraindicated. The Spanish moxifloxacin summaries of product characteristics (SmPCs) contraindicate moxifloxacin with antipsychotics and name pimozide among them. Their contraindications section also rules out giving moxifloxacin with other drugs that prolong the QT interval (moxifloxacin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label contraindicates pimozide with QT-prolonging drugs and states that pimozide should not be given with moxifloxacin (pimozide label, US Food and Drug Administration, FDA). The Spanish pimozide SmPC contraindicates pimozide with drugs known to prolong the QT interval (pimozide SmPC, AEMPS). The US moxifloxacin label says to avoid moxifloxacin with antipsychotics and other QT-prolonging drugs (moxifloxacin FDA label). No document states how long to wait after stopping pimozide before starting moxifloxacin. The mean elimination half-life of pimozide in people with schizophrenia is about 55 hours (pimozide SmPC, AEMPS). Moxifloxacin is contraindicated in QT prolongation, electrolyte disturbances (especially uncorrected low potassium), clinically relevant bradycardia, heart failure with reduced ejection fraction and a history of symptomatic arrhythmias (moxifloxacin SmPCs, AEMPS). Pimozide is contraindicated in QT prolongation, a history of arrhythmias, known low potassium or magnesium and clinically significant bradycardia (pimozide SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and periodically during treatment, and stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). If signs of arrhythmia appear, stop moxifloxacin and record an ECG (moxifloxacin SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b, version 1, 08/2026, sections 5.6 (QT Prolongation) and 7.5 (Drugs that Prolong QT)
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.3 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, secciones 4.3, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.5 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, sección 4.5